CRISPR Therapeutics AG (FRA:1CG)
Germany · Delayed Price · Currency is EUR | Market Cap | 4.23B -24.6% |
| Revenue (ttm) | 11.72M -64.8% |
| Net Income | -394.88M |
| EPS | -4.17 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 160 |
| Open | 44.45 |
| Previous Close | 44.45 |
| Day's Range | 44.08 - 44.45 |
| 52-Week Range | 37.60 - 65.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 3, 2026 |
About CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as deve... [Read more]
Financial Performance
In 2025, CRISPR Therapeutics AG's revenue was $3.51 million, a decrease of -90.59% compared to the previous year's $37.31 million. Losses were -$581.60 million, 58.8% more than in 2024.
Financial numbers in USD Financial StatementsNews
Crispr Therapeutics initiated with a Neutral at UBS
UBS initiated coverage of Crispr Therapeutics (CRSP) with a Neutral rating and $52 price target The company’s validated genome editing platform is a historic first with an approved cell therapy,…
Crispr Therapeutics price target lowered to $81 from $82 at BofA
BofA lowered the firm’s price target on Crispr Therapeutics (CRSP) to $81 from $82 and keeps a Buy rating on the shares as part of a Q3 earnings preview for…
CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026
ZUG, Switzerland and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310®, its investigational CRISPR/Cas9...
CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026
ZUG, Switzerland and BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company's Phase 1 clinical data of its in...
CRISPR Therapeutics AG Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
CASGEVY’s pediatric label expansion and strong payer coverage are driving rapid revenue growth, while three key assets—CTX310, zugo-cel, and CTX611—are advancing toward pivotal trials. The pipeline is supported by robust research, AI-driven productivity, and a focus on global expansion and next-generation gene editing.
CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
ZUG, Switzerland and BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Morgan Stanley 24th An...
Crispr Therapeutics durability data ‘encouraging,’ says Morgan Stanley
After Crispr Therapeutics (CRSP) presented durability data from its Phase 1 trial of CTX310 gene editing therapy targeting ANGPTL3, Morgan Stanley called the data “encouraging,” but adds that the firm...
CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026
-Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026- -Phase 1a clinical data for CTX310® continued to demonstrate robust, dose-dependent reduction...
CRISPR Therapeutics AG Slides: Corporate presentation
CRISPR Therapeutics AG has posted slides in relation to its latest quarterly earnings report, which was published on August 28, 2026.
Crispr Therapeutics price target raised to $55 from $48 at Goldman Sachs
Goldman Sachs analyst Salveen Richter raised the firm’s price target on Crispr Therapeutics (CRSP) to $55 from $48 and keeps a Neutral rating on the shares.
Crispr Therapeutics price target lowered to $82 from $83 at BofA
BofA lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $83 and keeps a Buy rating on the shares. The firm adjusted targets for several companies in…
Crispr Therapeutics price target raised to $55 from $48 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Crispr Therapeutics (CRSP) to $55 from $48 and keeps a Neutral rating on the shares.
Citi ups Crispr Therapeutics target on Casgvey momentum
Citi raised the firm’s price target on Crispr Therapeutics (CRSP) to $88 from $82 and keeps a Buy rating on the shares. The firm says Casgvey revenue beat its Q2…
Crispr Therapeutics price target raised to $88 from $82 at Citi
Citi raised the firm’s price target on Crispr Therapeutics (CRSP) to $88 from $82 and keeps a Buy rating on the shares.
Crispr Therapeutics reports Q2 EPS (94c), consensus ($1.18)
Reports Q2 revenue $10.18M, consensus $7.43M. “The second quarter reflected strong execution across CRISPR Therapeutics (CRSP)’ portfolio and platform,” said Samarth Kulkarni, Chairman and Chief Execu...
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026.
CRISPR Therapeutics AG Earnings release: Q2 2026
CRISPR Therapeutics AG released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
CRISPR Therapeutics AG Quarterly report: Q2 2026
CRISPR Therapeutics AG has published its Q2 2026 quarterly earnings report on August 3, 2026.
CRISPR Therapeutics (CRSP) Price Forecast: Dual Breakout Targets Higher Prices
CRISPR Therapeutics confirmed a dual breakout from inverse head and shoulders patterns, strengthening the bullish outlook and pointing to additional upside if resistance continues to give way.
Crispr Therapeutics assumed at Equal Weight from Underweight at Morgan Stanley
Morgan Stanley upgraded Crispr Therapeutics (CRSP) to Equal Weight from Underweight with a price target of $60, up from $33, as the analyst assumed coverage. The firm looks for improved…
CRISPR Therapeutics AG Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company is prioritizing cardiovascular and autoimmune programs, with five clinical trial readouts expected in the second half of the year. Key assets include CTX611, CTX310, and allogeneic CD19 zugo-cel, with pivotal trials planned for 2027 and a strong financial position supporting independent or partnered advancement.
CRISPR Therapeutics AG Transcript: 46th Annual William Blair Growth Stock Conference
The company is rapidly expanding its gene editing and siRNA pipeline, with CASGEVY's global launch progressing and multiple clinical readouts expected by late 2026. Strategic partnerships and innovation in conditioning regimens and delivery platforms position it for leadership in biotech.
CRISPR Therapeutics AG Transcript: Jefferies Global Healthcare Conference 2026
A broad pipeline is advancing with multiple late-stage assets, including CTX310, zugo-cel, and CTX611, all expected to reach key clinical milestones by year-end. CASGEVY commercialization is accelerating, and several new programs are poised for significant data readouts in the next 12 months.
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
ZUG, Switzerland and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team are scheduled to participate in the followin...